Host and viral determinants of hepatitis C virus species tropism
Host and viral determinants of hepatitis C virus species tropism
批准号:
9193819
负责人:
Essanna Sequel Gray
金额:
$3.88万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-08-01 至 2019-07-31
关键词:
Adaptor Signaling ProteinAmino AcidsAnimal ModelAnimalsAntiviral AgentsBacteriophagesCD81 geneCell LineCellsCleaved cellDevelopmentDisciplineEventEvolutionExhibitsFerretsGenerationsGeneticGenotypeGoalsHCV Animal ModelsHepG2Hepatitis CHepatitis C VaccineHepatitis C virusHepatitis C-Like VirusesHepatocyteHumanHuman Cell LineImmuneImmune responseImmune systemImmunocompetentImmunosuppressionIndividualInfectionIntegration Host FactorsInterferonsKnock-outLeadLife Cycle StagesMalignant neoplasm of liverMapsMediatingMethodsMitochondriaModelingMonitorMutationNatural ImmunityOrthologous GenePan GenusPathogenesisPatientsPeptide HydrolasesPharmaceutical PreparationsPopulationPredispositionProcessProteinsResearchResistanceSignal TransductionSpecies SpecificityStagingSystemTight JunctionsTissuesTropismUnited StatesVaccinesVariantViralViral GenomeVirusVirus Replicationanti-hepatitis Cbasecostfitnessglobal healthin vivoinnovationinsightliver transplantationmutantoccludinpathogenresearch studyresponsevaccine developmentvirus geneticsvirus tropism
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Hepatitis C virus (HCV) is one of the leading causes of liver cancer and liver transplants in the United States.
While current treatments show considerable promise, many patients worldwide will not benefit from these
treatments due to cost and required long-term administration and monitoring. Furthermore, cured patients are
not protected from new HCV infection. A protective vaccine would greatly augment the efforts to reduce the
global health impact caused by HCV. An immunocompetent animal model would aid development of an
effective HCV vaccine however; this effort is impeded by HCV's strict species-tropism, as efficient HCV
infection is restricted to only humans and chimpanzees. The experiments proposed in this application are
aimed at studying the basic mechanisms by which HCV tropism is regulated, and are based on our hypothesis
that HCV species-specific tropism is influenced, at least in part, by differences in the capacity for HCV to enter
host cells and suppress innate immune responses in disparate species. We recently observed that ferrets are
able to support HCV infection in vivo, but at much weaker levels than observed in humans and chimpanzees.
We seek to understand what controls viral tropism of HCV during both entry and post-entry events and will
explore species-specific blocks to HCV infection in ferrets. Our preliminary studies identified that the ferret
version of the tight junction protein occludin (OCLN) does not function efficiently as an HCV entry factor. To
define the cellular determinants of ferret OCLN's activity as an HCV entry factor, we will map critical residues
that influence its function as an entry factor during HCV entry. We will also select for mutations in the HCV
genome that will allow more efficient use of ferret OCLN. Furthermore, we have found that HCV suppression of
the innate immune response is also influenced by species-specific factors, as we have found that HCV is
unable to cleave ferret MAVS. We propose experiments to examine host and viral determinants that influence
HCV cleavage of ferret MAVS and determine how inadequate suppression of the innate immune system in
ferrets by HCV influences viral replication. By identifying species-specific entry, replication and innate immunity
restrictions to HCV infection across a wide range of species and defining how these blocks contribute to HCV
viral tropism, we can devise methods for efficient HCV infection in a range of species as well as provide insight
on how host-pathogen interactions impact the life cycles and host susceptibility for a range of other viruses
with similar replication and immune evasion mechanisms.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金